Ina Hasani

Ina Hasani is the National Director of Business Development at Lyfegen, responsible for leading business development efforts in Canada. With nearly 10 years of experience in life sciences, including key roles at Novartis and Pfizer, Ina is a results-oriented and strategic leader with deep expertise in healthcare strategy, market access, and health economics.

Passionate about transforming healthcare and improving patient outcomes, she has a proven track record of successfully launching innovative treatments by effectively navigating the complexities of the Canadian healthcare landscape. Ina is highly regarded for her knowledge in health economics, patient access, and commercial strategy.

Ina excels in managing and integrating digital solutions to enhance patient outcomes, demonstrating a keen ability to navigate regulatory challenges and align emerging technologies with healthcare system needs. Her expertise in driving change and navigating complex environments has positioned her as a leader in healthcare innovation.

Ina holds an MBA with a finance focus from the Rotman School of Management, an MSc in Pharmaceutical Science (Pharmacoeconomics) from Université de Montréal, and a BSc in Pharmacology from Université de Sherbrooke.